Physician profile
Mathews Ninan
NPI 1659351716
$6,734.68
in general payments reported to CMS, 2019-2025
30 companies · $15.70 in 2025
The $15.70 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,451 · 2020: $335 · 2021: $571 · 2022: $3,363 · 2023: $264 · 2024: $735 · 2025: $15.70.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,000 · Gift: $14.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $999.74 |
| Gift | $14.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,749.79 | 2021-2023 | |
| Abbott Laboratories | $1,487.93 | 2019-2023 | Freestyle Libre 3 |
| Intuitive Surgical, INC. | $675.33 | 2024 | |
| Novo Nordisk INC | $322.25 | 2021-2023 | Ozempic, Rybelsus |
| Lilly USA, LLC | $221.54 | 2021-2023 | Mounjaro |
| Bayer Healthcare Pharmaceuticals INC. | $145.09 | 2021-2023 | |
| Abiomed | $134.36 | 2020 | |
| Boston Scientific Corporation | $126.53 | 2019-2021 | |
| Horizon Therapeutics Plc | $124.78 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $83.18 | 2021-2023 | |
| Exact Sciences Corporation | $75.07 | 2024-2025 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $72.09 | 2021-2023 | Seglentis |
| Zyla Life Sciences, INC. | $67.75 | 2019 | |
| Amgen INC. | $46.69 | 2021-2022 | |
| Pfizer INC. | $45.46 | 2021-2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $43.53 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $41.83 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $39.38 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $31.57 | 2021 | |
| Astellas Pharma US INC | $26.71 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.40 | 2023 | Jardiance |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.45 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.07 | 2021 | |
| Sanofi-Aventis U.S. LLC | $18.76 | 2021 | |
| Medtronic USA, INC. | $18.69 | 2019 | |
| Genentech USA, INC. | $17.09 | 2020 | |
| Ironshore Pharmaceuticals INC. | $17.05 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.99 | 2023 | Trulance, Xifaxan |
| Antares Pharma, INC. | $14.97 | 2021 | |
| Eisai INC. | $13.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mathews Ninan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.